You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY State of the art techniques result inyear solid organ graft loss ofto overin cardiopulmonary organ transplantationEstablishment of donor specific immunological toleranceDSITa condition in which a recipient accepts a transplant without immunosuppressionwhile retaining the ability to fight infectionswould reduce graft loss and transplant related complicationsThe only identified metho ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. New Topical Therapies for Psoriasis

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Psoriasis is a common, inflammatory disease of the skin characterized by hyperproliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. In the current studies, we are in ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Newborn Screening for Sex Chromosome Disorders

    SBC: JS GENETICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an entire, or a portion of an X-chromosome is deleted. The incidence of TS 1 in 1,500 to 2,000 live female births. Features include primary hypogonadism, renal abnormalities and cardiac problems. Girls with TS are short and have an average adult height of 4 feet 6 inches. Ye ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  5. Modified HER-2 Tumor Antigens for Vaccination in Cancer

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Breast cancer remains one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing a novel tumor immunotherapy by using cryptic peptides of Her-2 protein and modified Her-2 peptides, both of which break immune tolerance to ?self? tumor antigens expressed on breast ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Microfluidic Nitric Oxide Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    PROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Live cell and HCS assays to quantify production of cardiomyocytes from stem cells

    SBC: VALA SCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Heart failure is a leading cause of mortality in modern society, and is the result from the death of cardiac myocytes. Contractile function of failing hearts can be restored by injecting the heart with embryonic stem cell-derived cardiac myocytes (ESCMs) which integrate into the host tissue. To facilitate production of ESCMs, high throughput screening systems a ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  8. Isotopically Labeled Nucleotides for Biomolecular NMR

    SBC: CASSIA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of the proposed research is to scale up the production and manufacture of high-value ribonucleoside triphosphates containing stable isotope labels. The use for these products is in biomolecular studies of RNA structure using Nuclear Magnetic Resonance (NMR) spectroscopy. The market for these products is structural biology groups in academic and industr ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Impact of LifeSkills Training on Blood Pressure in Youth

    SBC: WILLIAMS LIFESKILLS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Essential hypertension (EH) has its pathobiologic origins in childhood. Since blood pressure (BP) ranking tracks from late childhood onward, adolescents with elevated BP are at risk for development of EH later in life. The need for development of effective primary prevention programs for EH highlighted the NHLBI is corroborated by recent BP rises in youth. The ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Identification of Novel ACTH Small Molecule Antagonists

    SBC: Chemdiv, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of drugs based on the MC2R antagonists will directly benefit children with CAH and Cushing's diseases, and will help us to understand MC2R's role in metabolic pathways. The long term goal of this project is to discover small molecule inhibitors of MC2 receptor and develop drug to treat several metabolic diseases including CAH and Cushing's diseases ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government